Фармакотерапия острых респираторных инфекций, вызванных вирусами гриппа
- Авторы: Зырянов С.К.1,2, Бутранова О.И.1, Гайдай Д.С.3, Крышень К.Л.3
-
Учреждения:
- ФГАОУ ВО «Российский университет дружбы народов»
- ГБУ «Городская клиническая больница №24» Департамента здравоохранения г. Москвы
- ЗАО «Санкт-Петербургский институт фармации»
- Выпуск: Том 93, № 1 (2021)
- Страницы: 114-124
- Раздел: Обзоры
- URL: https://journals.rcsi.science/0040-3660/article/view/61914
- DOI: https://doi.org/10.26442/00403660.2021.01.200551
- ID: 61914
Цитировать
Полный текст
Аннотация
Вирус гриппа рутинно вносит наиболее весомый вклад в формирование ежегодного уровня заболеваемости острыми респираторными инфекциями с пиком в зимний период. Высокий уровень мутагенного потенциала вирусов гриппа является стандартным фактором, определяющим сложность рационального выбора фармакотерапии. Предстоящий эпидемиологический сезон 2020–2021 гг. несет для практического звена здравоохранения дополнительные вызовы, связанные с широким распространением в человеческой популяции новой инфекции, вызванной вирусом SARS-CoV-2 и поражающей в числе многих органов и систем респираторную систему. Адекватный выбор инструментов фармакотерапии должен базироваться на высокой эффективности и безопасности применяемых препаратов, с возможным снижением таких отрицательных факторов, как полипрагмазия. Настоящий обзор включает сравнительные фармакологические характеристики препаратов, обладающих активностью в отношении РНК-содержащих вирусов, наряду с параметрами их клинической эффективности.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Сергей Кенсаринович Зырянов
ФГАОУ ВО «Российский университет дружбы народов»; ГБУ «Городская клиническая больница №24» Департамента здравоохранения г. Москвы
Email: butranova-oi@rudn.ru
ORCID iD: 0000-0002-6348-6867
д.м.н., проф., зав. каф. общей и клинической фармакологии ФГАОУ ВО РУДН, зам. глав. врача ГБУ ГКБ №24
Россия, 117198, Москва, ул. Миклухо-Маклая, 6; МоскваОльга Игоревна Бутранова
ФГАОУ ВО «Российский университет дружбы народов»
Автор, ответственный за переписку.
Email: butranova-oi@rudn.ru
ORCID iD: 0000-0001-7729-2169
к.м.н., доц. каф. общей и клинической фармакологии Медицинского института ФГАОУ ВО РУДН
Россия, 117198, Москва, ул. Миклухо-Маклая, 6Дмитрий Сергеевич Гайдай
ЗАО «Санкт-Петербургский институт фармации»
Email: butranova-oi@rudn.ru
ORCID iD: 0000-0002-8773-5717
биолог отд. токсикологии и микробиологии, рук. исследований, ЗАО «Санкт-Петербургский институт фармации»
Россия, 188663, Россия, Ленинградская область, Всеволожский район, г.п. Кузьмоловский корп. 245Кирилл Леонидович Крышень
ЗАО «Санкт-Петербургский институт фармации»
Email: butranova-oi@rudn.ru
ORCID iD: 0000-0003-1451-7716
к.б.н., ст. науч. сотр. – рук. отд. токсикологии и микробиологии ЗАО «Санкт-Петербургский институт фармации»
Россия, 188663, Россия, Ленинградская область, Всеволожский район, г.п. Кузьмоловский корп. 245Список литературы
- Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis. 2020;39(7):1201-08. doi: 10.1007/s10096-020-03840-9
- Dawood FS, Chung JR, Kim SS, et al. Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness – United States, February 2020. MMWR Morb Mortal Wkly Rep 2020;69:177-82. doi: 10.15585/mmwr.mm6907a1
- Duwe S. Influenza viruses – antiviral therapy and resistance. GMS Infect Dis. 2017;5:Doc04. doi: 10.3205/id000030
- Esposito S, Molteni CG, Colombo C, et al. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol. 2010;48(1):62-5. doi: 10.1016/j.jcv.2010.02.019
- Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009;83(1):90-3. doi: 10.1016/j.antiviral.2009.03.003
- Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Semin Immunopathol. 2017;39(5):541-50. doi: 10.1007/s00281-017-0636-y
- Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus Res. 2015;209:11-22. doi: 10.1016/j.virusres.2015.02.003
- La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol. 2007;85(2):85-92. doi: 10.1038/sj.icb.7100026
- Oshansky CM, Gartland AJ, Wong SS, et al. Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. Am J Respir Crit Care Med. 2014;189(4):449-62. doi: 10.1164/rccm.201309-1616OC
- Dienz O, Rud J, Eaton S, et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 2012;5:258-66. doi: 10.1038/mi.2012.2
- Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355-62. doi: 10.1038/s41577-020-0331-4
- Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970-5. doi: 10.1073/pnas.2005615117
- Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. Preprint at medRxiv. 2020. doi: 10.1101/2020.04.01.20048561
- Toots M, Plemper RK. Next-generation direct-acting influenza therapeutics. Transl Res. 2020;220:33-42. doi: 10.1016/j.trsl.2020.01.005
- Davidson S. Treating Influenza Infection, From Now and Into the Future. Front Immunol. 2018;9:1946. doi: 10.3389/fimmu.2018.01946
- Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6:28. doi: 10.1038/s41421-020-0169-8
- Gibiansky L, Ravva P, Parrott NJ, et al. Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants. Clin Pharmacol Ther. 2020;108(1):126-35. doi: 10.1002/cpt.1791
- Malosh R, Martin E, Heikkinen T, et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018;66(10):1492-500. doi: 10.1093/cid/cix1040
- Chambers CD, Johnson D, Xu R, et al.; OTIS Collaborative Research Group. Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants. Birth Defects Res. 2019;111(19):1487-93. doi: 10.1002/bdr2.1566
- Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. doi: 10.1136/bmj.g2545
- Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2012;7:7-13. doi: 10.1111/irv.12046
- Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2017;135(2):148-60. doi: 10.1111/ane.12629
- Nakamura K, Schwartz BS, Lindegårdh N, et al. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis. 2010;50(7):e47-9. doi: 10.1086/651166
- Muraki K, Hatano N, Suzuki H, et al. Oseltamivir blocks human neuronal nicotinic acetylcholine receptor-mediated currents. Basic Clin Pharmacol Toxicol. 2015;116(2):87-95. doi: 10.1111/bcpt.12290
- Suzuki M, Masuda Y. Effect of a neuraminidase inhibitor (oseltamivir) on mouse jump-down behavior via stimulation of dopamine receptors. Biomed Res. 2008;29(5):233-8. doi: 10.2220/biomedres.29.233
- Han N, Oh JM, Kim IW. Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews. Sci Rep. 2020;10(1):3116. doi: 10.1038/s41598-020-60068-5
- Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22-9. doi: 10.1016/j.coviro.2014.04.009
- Kim HM, Lee N, Kim MS, et al. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea. Virol J. 2020;17(1):94. doi: 10.1186/s12985-020-01375-1
- Li TC, Chan MC, Lee N. Clinical Implications of Antiviral Resistance in Influenza. Viruses. 2015;7(9):4929-44. doi: 10.3390/v7092850
- Gillman A, Muradrasoli S, Söderström H, et al. Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir. PLoS One. 2013;8(8):e71230. doi: 10.1371/journal.pone.0071230
- Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032
- Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl. 1):21-31. doi: 10.2165/00003088-199936001-00003
- Shelton MJ, Lovern M, Ng-Cashin J, et al. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother. 2011;55(11):5178-84. doi: 10.1128/AAC.00703-11
- Torti C, Mazzitelli M, Longhini F, et al. Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series. BMC Infect Dis. 2019;19(1):858. doi: 10.1186/s12879-019-4530-1
- Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547. doi: 10.1136/bmj.g2547
- Abed Y, Boivin G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open Forum Infect Dis. 2017;4(3):ofx105. doi: 10.1093/ofid/ofx105
- Alame MM, Massaad E, Zaraket H. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections. Front Microbiol. 2016;7:450. doi: 10.3389/fmicb.2016.00450
- Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006;69:39-45. doi: 10.1016/j.antiviral.2005.10.002
- Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012–2013 season. J Infect Chemother. 2015;21(1):39-42. doi: 10.1016/j.jiac.2014.08.030
- Saisho Y, Ishibashi T, Fukuyama H, et al. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. Antivir Ther. 2017;22(4):313-23. doi: 10.3851/IMP3104
- Lee J, Park JH, Jwa H, Kim YH. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis. Yonsei Med J. 2017;58(4):778-85. doi: 10.3349/ymj.2017.58.4.778
- Chen JY, Wei SK, Lai CC, et al. A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment. Medicina (Kaunas). 2020;56(2):63. doi: 10.3390/medicina56020063
- Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother. 2010;21(2):71-84. doi: 10.3851/IMP1688
- Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011–2012 influenza season. J Infect Chemother. 2014;20(2):81-5. doi: 10.1016/j.jiac.2013.07.013
- Yoshihara K, Ishizuka H, Kubo Y. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug Metab Pharmacokinet. 2013;28(5):416-26. doi: 10.2133/dmpk.dmpk-12-rg-115
- Ishizuka H, Toyama K, Yoshiba S, et al. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Antimicrob Agents Chemother. 2012;56(7):3873-8. doi: 10.1128/AAC.06456-11
- Minakami H, Kubo T, Nakai A, et al. Pregnancy outcomes of women exposed to laninamivir during pregnancy. Pharmacoepidemiol Drug Saf. 2014;23(10):1084-7. doi: 10.1002/pds.3684
- Tochino Y, Yoshii N, Fujioka M, et al. Effect of four neuraminidase inhibitors on influenza in Osaka, Japan: An eight-year survey. J Gen Fam Med. 2019;21(1):18-23. doi: 10.1002/jgf2.286
- Koseki N, Kaiho M, Kikuta H, et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011–2012 season. Influenza Other Respir Viruses. 2014;8(2):151-8. doi: 10.1111/irv.12147
- Higashiguchi M, Matsumoto T, Fujii T. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Antivir Ther. 2018;23(2):157-65. doi: 10.3851/IMP3189
- McKimm-Breschkin JL, Barrett S. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. Antiviral Res. 2015;114:62-6. doi: 10.1016/j.antiviral.2014.12.004
- Ng KE. Xofluza (Baloxavir Marboxil) for the Treatment Of Acute Uncomplicated Influenza. P T. 2019;44(1):9-11. PMID: 30675086
- Taieb V, Ikeoka H, Ma FF, et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019;35(8):1355-64. doi: 10.1080/03007995.2019.1584505
- Yoshii N, Tochino Y, Fujioka M, et al. The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice. Intern Med. 2020;59(12):1509-13. doi: 10.2169/internalmedicine.4117-19
- Baker J, Block SL, Matharu B, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-5. doi: 10.1097/INF.0000000000002747
- Takashita E, Daniels RS, Fujisaki S, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018. Antiviral Res. 2020;175:104718. doi: 10.1016/j.antiviral.2020.104718
- Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. doi: 10.1016/j.pharmthera.2020.107512
- Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020;108(2):242-7. doi: 10.1002/cpt.1844
- Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-63. doi: 10.2183/pjab.93.027
- Wang Y, Fan G, Salam A, et al. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020;221(10):1688-98. doi: 10.1093/infdis/jiz656
- Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45-51. doi: 10.1016/S2055-6640(20)30016-9
- Takashita E, Ejima M, Ogawa R, et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 2016;132:170-7. doi: 10.1016/j.antiviral.2016.06.007
- Li H, Yang L, Liu FF, et al. Overview of therapeutic drug research for COVID-19 in China. Acta Pharmacol Sin. 2020:1-8. doi: 10.1038/s41401-020-0438-y
- Nittari G, Pallotta G, Amenta F, Tayebati SK. Current pharmacological treatments for SARS-COV-2: A narrative review. Eur J Pharmacol. 2020;882:173328. doi: 10.1016/j.ejphar.2020.173328
- Available from: https://static-0.minzdrav.gov.ru/system/attachments/ attaches/000/052/550/original/%D0%9C%D0%A0_COVID-19_%28v9%29.pdf?1603788097
- Kotey E, Lukosaityte D, Quaye O, et al. Current and Novel Approaches in Influenza Management. Vaccines (Basel). 2019;7(2):53. doi: 10.3390/vaccines7020053
- Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84-94. doi: 10.1016/j.antiviral.2014.04.006
- Одноворов А.И., Гребенникова Т.В., Плетенева Т.В. Специфическая терапия гриппа: современное состояние и перспективы (обзор). Разработка и регистрация лекарственных средств. 2020;9(1):83-91 [Odnovorov AI, Grebennikova TV, Pleteneva TV. Specific Influenza Therapy: Current State and Prospects (Review). Drug Development & Registration. 2020;9(1):83-91 (In Russ.)]. doi: 10.33380/2305-2066-2020-9-1-83-91
- Silin DS, Lyubomska OV, Ershov FI, et al. Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharm Des. 2009;15(11):1238-47. doi: 10.2174/138161209787846847
- Proskurnina EV, Izmailov DY, Sozarukova MM, et al. Antioxidant Potential of Antiviral Drug Umifenovir. Molecules. 2020;25(7):1577. doi: 10.3390/molecules25071577
- Deng P, Zhong D, Yu K, et al. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013;57(4):1743-55. doi: 10.1128/AAC.02282-12
- Шамшева О.В., Молочкова О.В. Спектр применения отечественного противовирусного препарата в педиатрии. Детские инфекции. 2015;14(4):26-30 [Shamsheva OV, Molochkova OV. The Range of Application of Domestic Antiviral Drug in Рediatrics. Children Infections. 2015;14(4):26-30 (In Russ.)]. doi: 10.22627/2072-8107-2015-14-4-26-30
- Пшеничная Н.Ю., Булгакова В.А., Львов Н.И. и др. Клиническая эффективность умифеновира при гриппе и ОРВИ (исследование АРБИТР). Терапевтический архив. 2019;91(3):56-63 [Pshenichnaya NY, Bulgakova VA, Lvov NI, et al. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(3):56-63 (In Russ.)]. doi: 10.26442/00403660.2019.03.000127
- Huang D, Yu H, Wang T, et al. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020;10.1002/jmv.26256. doi: 10.1002/jmv.26256
- Zarubaev VV, Garshinina AV, Kalinina NA, et al. Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments. Pharmaceuticals (Basel). 2011;4(12):1518-34. doi: 10.3390/ph4121518
- Ашахер Т., Крохин А., Кузнецова И. и др. Влияние препарата Ингавирин® (имидазолилэтанамида пентандиовой кислоты) на интерфероновый статус клеток в условиях вирусной инфекции. Эпидемиология и инфекционные болезни. 2016;21(4):196-205 [Aschacher Т, Krokhin А, Kuznetsova I, et al. Effect of the antiviral drug Ingavirin® (imidazolyl ethanamide pentandioic acid) on the interferon status of cells under conditions of viral infection. Epidemiology and Infectious Diseases. 2016;21(4):196-205 (In Russ.)]. doi: 10.18821/1560-9529-2016-21-4-196-205
- Соколова Т.М., Полосков В.В., Шувалов А.Н. и др. Сигнальные TLR/RLR-механизмы иммуномодулирующего деиствия препаратов ингавирин и тимоген. Российский биотерапевтический журнал. 2019;18(1):60-6 [Sokolova TM, Poloskov VV, Shuvalov AN, et al. Signaling TLR/RLR-mechanisms of immunomodulating action of ingavirin and thymogen preparations. Rus J Biother. 2019;18(1):60-6 (In Russ.)]. doi: 10.17650/1726-9784-2019-18-1-60-66
- Nicholson EG, Munoz FM. A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children. Clin Ther. 2018;40(8):1268-81. doi: 10.1016/j.clinthera.2018.06.014
- Дзюблик А.Я., Симонов С.С., Ячник В.А. Клиническая эффективность и безопасность противовирусного препарата Ингавирин в комплексном лечении больных с обострением бронхиальной астмы, ассоциированным с ОРВИ. Пульмонология. 2013;(6):43-50 [Dzyublik AY, Simonov SS, Yachnik VA. Clinical efficacy and safety of antiviral drug Ingavirin in patients with asthma exacerbations caused by an acute respiratory viral infection (ARVI). Pulmonologiya. 2013;(6):43-50 (In Russ.)]. doi: 10.18093/0869-0189-2013-0-6-765-775
- Шульдяков А.А., Ляпина Е.П., Кузнецов В.И. и др. Клинико-эпидемиологическая эффективность противовирусного препарата Ингавирин®. Пульмонология. 2012;(4):62-9 [Shuldyakov AA, Lyapina EP, Kuznetsov VI, et al. Clinical and epidemiological efficacy of antiviral drug Ingavirin. Pulmonologiya. 2012;(4):62-9 (In Russ.)]. doi: 10.18093/0869-0189-2012-0-4-62-69
- Haltner-Ukomadu E, Gureyeva S, Burmaka O, et al. In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Pharm. 2018;86(1):3. doi: 10.3390/scipharm86010003
- Walker AP, Fan H, Keown JR, et al. Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases. Preprint. bioRxiv. 2020;2020.04.21.053017. doi: 10.1101/2020.04.21.053017
- Cocking D, Cinatl J, Boltz DA, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 2018;62(2):191-5. doi: 10.4149/av_2018_211
- Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. doi: 10.1177/2040206618811416
- Пшеничная Н.Ю., Булгакова В.А., Волчкова Е.В. Обзор текущих и перспективных направлений противовирусной терапии гриппа и острых респираторных вирусных инфекций в России. Терапевтический архив. 2019;91(11):105-9 [Pshenichnaya NY, Bulgakova VA, Volchkova EV, et al. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(11):105-9 (In Russ.)]. doi: 10.26442/00403660.2019.11.000454
- Zupanets I, Zhulai T, Shebeko S, et al. Histomorphological Study of a New Nasal Spray with Anti-inflammatory Properties Efficacy in Rabbits with Rhinosinusitis. Med Arch. 2020;74(1):8-13. doi: 10.5455/medarh.2020.74.8-13
- Zhulai TS. The preclinical study of a new nasal spray with the anti-inflammatory properties: the effect on the leukotriene-induced inflammation. Clin Pharm. 2018;22(4):27-33. doi: 10.24959/cphj.18.1473
- Лиознов Д.А., Карнаухова Е.Ю., Зубкова Т.Г., Шахланская Е.В. Оценка эффективности схемы лечения ОРВИ, включающей этиотропную (энисамия йодид) и симптоматическую терапию. Терапевтический архив. 2020;92(3):50-5 [Lioznov DA, Karnaukhova EJ, Zubkova TG, Shakhlanskaya EV. Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(3):50-5 (In Russ.)]. doi: 10.26442/00403660.2020.03.000572
- Available from: https://www.cdc.gov/flu/professionals/antivirals/ summary-clinicians.htm
- Available from: https://static-0.rosminzdrav.ru/system/attachments/ attaches/000/050/033/original/RESP_REC_V2.pdf
- Available from: https://clinline.ru/reestr-klinicheskih-issledovanij/ 600-27.10.2020.html